Comparative analysis of tacrolimus (FK506) in whole blood liver transplant recipients by PRO-TRAC enzyme-linked immunosorbent assay and microparticle enzyme immunoassay IM(x) methods

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 706-709

  Brunet, M ^a,c   Pou, L ^b   Torra, M ^a   Lopez R ^b   Rodamilans, M ^a   Corbella, J ^a  

^a Infectious Diseases Unit   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Cross reactivity; Enzyme linked immunosorbent assay; Immunoassay; Microparticle enzyme immunoassay; Monitoring; Tacrolimus

Indexed keywords

TACROLIMUS;

ACCURACY; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; LIVER TRANSPLANTATION; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL;

DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; REPRODUCIBILITY OF RESULTS; TACROLIMUS;

EID: 0029826650     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00013     Document Type: Article

References (21)

1. Schreider SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-42.
2. Baumann G. Molecular mechanism of immunosuppressive agents. Transplant Proc 1992;24(suppl 2):4-7.
3. Schwaninger M, Blume R, Oetjen E, Knepel W. The immunosuppressive drugs cyclosporin A and FK506 inhibit calcineurin phosphatase activity and gene transcription mediated through the cAMP responsive element in a nonimmune cell line. Naunyn Schmiedebergs Arch Pharmacol 1993;348:541-5.
4. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994;26:3272-5.
5. Kino T, Hatanaka H, Miyata S, et al. FK506: a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot 1987;40:1256-65.
6. Thomson AW. FK506 - how much potential? Immunol Today 1989;10:6-9.
7. Wallemacq PE, Reding R. FK506 (Tacrolimus), a novel immunosupressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin Chem 1993;39:2219-28.
8. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
9. Busuttil RW, McDiarmid S, Klintmalm GB, Goldstein R, Miller CM, Schwartz M, et al. The US Multicenter FK06 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110-5.
10. Neuhaus P, Picklemayr R, Williams R. European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;344:423-8.
11. The European FK506 Multicenter Liver Study Group. Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. Transplant Proc 1994;26:3260-3.
12. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transpantation. Transplantation 1994;58: 170-8.
13. Mueller AR, Platz KP, Bechstein WO, et al. Neurotoxicity after orthotopic liver transplantation. Transplantation 1994;58:155-69.
14. Winkler M, Ringe B, Baumann J, Loss M, Wonigeit K, Pichlmayr R. Plasma vs. whole blood for therapeutic drug monitoring of patients receiving FK506 for immunosuppression. Clin Chem 1994;40:2247-53.
15. Schwartz M, Holst D, Facklam D, Buell D, and The U.S. Multicenter FK506 Dose Optimization Study Group. FK506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995;27:1107.
16. Kobayashi M, Tamura K, Katayama N, et al. FK506 Assay past and present: characteristics of FK506 ELISA. Transplant Proc 1991;23:2725-9.
17. Friob MC, Hassoun A, Lattine D, Lhoést G, Otte JB, Wallemacq PE. A combined HPLC-ELISA evaluation of FK506 in transplant patients. Transplant Proc 1991;23:2750-2.
18. x analyzer. Transplant Proc 1991;23:2748-9.
19. Warty V, Zuckerman S, Venkataramanan R, Lever J, Fung J, Starzl T. FK506 measurement: comparison of different analytical methods. Ther Drug Monit 1993;15:204-8.
20. Wallemacq PE, Firdaous I, Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours. Clin Chem 1993;39:1045-9.
21. x analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit 1994;16:287-92.